TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study
Brief Summary: To analyze the weight gain of very low birth weight infants during a minimum period of three weeks before 36 weeks postmenstrual age when infants are fed with breast milk that has been individually fortified.


Options:
A: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Arm Label: Routine fortification of breast milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Routine fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Routine fortification of breast milk; Assigned to Arm(s): Routine fortification of breast milk
B: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk
C: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation
D: Arm Label: Intervention group; Type: OTHER; Interventions: Dietary Supplement: Addition of human milk fortifiers according to human milk analysis | Intervention Type: DIETARY_SUPPLEMENT; Name: Addition of human milk fortifiers according to human milk analysis; Assigned to Arm(s): Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study
Brief Summary: To analyze the weight gain of very low birth weight infants during a minimum period of three weeks before 36 weeks postmenstrual age when infants are fed with breast milk that has been individually fortified.


Options:
A: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
B: Arm Label: Experimental Human Milk Fortifier; Type: EXPERIMENTAL; Interventions: Other: Experimental human milk fortifier | Arm Label: Control Human Milk Fortifier; Type: ACTIVE_COMPARATOR; Interventions: Other: Control human milk fortifier | Intervention Type: OTHER; Name: Experimental human milk fortifier; Assigned to Arm(s): Experimental Human Milk Fortifier | Intervention Type: OTHER; Name: Control human milk fortifier; Assigned to Arm(s): Control Human Milk Fortifier
C: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk
D: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Brief Summary: The purpose of this study is to determine if PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery to create an arteriovenous fistula is safe and improves the patency of your fistula. PRT-201 is a protein that has been shown to help keep vessels open ("patent") when applied to the outside surface of the blood vessels (arteries and veins) in AVF patients in a previous study.


Options:
A: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): 2, PRT-201
B: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GTN patch; Type: EXPERIMENTAL; Interventions: Drug: GTN patch | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo comparator | Intervention Type: DRUG; Name: GTN patch; Assigned to Arm(s): GTN patch | Intervention Type: DRUG; Name: placebo comparator; Assigned to Arm(s): Placebo patch
D: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Brief Summary: The purpose of this study is to determine if PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery to create an arteriovenous fistula is safe and improves the patency of your fistula. PRT-201 is a protein that has been shown to help keep vessels open ("patent") when applied to the outside surface of the blood vessels (arteries and veins) in AVF patients in a previous study.


Options:
A: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholecalciferol; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: control group; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: Far infrared therapy; Type: EXPERIMENTAL; Interventions: Device: WSTM TY101 FIR emitter (Far infrared therapy) | Intervention Type: DEVICE; Name: WSTM TY101 FIR emitter (Far infrared therapy); Assigned to Arm(s): Far infrared therapy | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Health Benefits Associated With Consumption of Solar Disinfection of Drinking Water by Children Under Age 5 Years, With Particular Emphasis on Dysentery and Childhood Diarrhoea
Brief Summary: SODISWATER was a health impact assessment study investigating the effect of sunlight to inactivate microbial pathogens in drinking water. This study was carried out by observing whether children younger than 5 years old who drink solar disinfected water were healthier than those who did not. Health was measured by how often the children had diarrhoea or dysentery.

Caregivers for the participants were given plastic bottles to place in the sun, water samples were then collected from these plastic bottles to be analyzed. They were also requested to fill in diarrhea diaries.

TESTABLE RESEARCH HYPOTHESES:

Health Impact Assessment: Children who use solar disinfected water will have:

(a) lower morbidity due to non-bloody diarrhoea and bloody diarrhoea (c) increased growth rates (d) lower mortality (e) increased family productivity (f) decreased care-giver burden (g) increased school attendance


Options:
A: Arm Label: Existing water management and cooking practices; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Provision of water filters and improved cookstoves; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Household drinking water filters and cookstoves | Intervention Type: BEHAVIORAL; Name: Household drinking water filters and cookstoves; Assigned to Arm(s): Provision of water filters and improved cookstoves
B: Intervention Type: DRUG; Name: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding for 6 months postpartum; Assigned to Arm(s): N/A
C: Arm Label: SODIS Bottles given; Type: ACTIVE_COMPARATOR; Interventions: Other: SODIS Bottle | Arm Label: Usual practices; Type: ACTIVE_COMPARATOR; Interventions: Other: SODIS Bottle | Intervention Type: OTHER; Name: SODIS Bottle; Assigned to Arm(s): SODIS Bottles given, Usual practices
D: Arm Label: Solar disinfection of drinking water; Type: OTHER; Interventions: Other: Solar disinfection in transparent containers (plastic bottles) | Intervention Type: OTHER; Name: Solar disinfection in transparent containers (plastic bottles); Assigned to Arm(s): Solar disinfection of drinking water

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration
Brief Summary: Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.


Options:
A: Arm Label: Bevacizumab 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab 1 | Arm Label: Bevacizumab 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab 1; Assigned to Arm(s): Bevacizumab 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab 2
B: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vaccination of HIV-uninfected Pregnant Women With Trivalent Influenza Vaccine in the Prevention of Influenza Illness During Early Infancy and in Mothers: Randomized Controlled Phase III Trial Evaluating Safety, Immunogenicity and Efficacy
Brief Summary: Randomised, double blind, placebo controlled trial to assess safety, immunogenicity and efficacy of Trivalent Influenza vaccine in HIV uninfected pregnant women


Options:
A: Arm Label: CSL425 (7.5 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: CSL425 (15 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: CSL425 (30 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CSL425; Assigned to Arm(s): CSL425 (7.5 mcg) | Intervention Type: BIOLOGICAL; Name: CSL425; Assigned to Arm(s): CSL425 (15 mcg), CSL425 (30 mcg) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: treatment; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus rhamnosus, Biological: Influenza Virus Vaccine Live, Intranasal | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo control, Biological: Influenza Virus Vaccine Live, Intranasal | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus; Assigned to Arm(s): treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo control; Assigned to Arm(s): placebo | Intervention Type: BIOLOGICAL; Name: Influenza Virus Vaccine Live, Intranasal; Assigned to Arm(s): placebo, treatment
C: Arm Label: Trivalent influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
D: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vaccination of HIV-uninfected Pregnant Women With Trivalent Influenza Vaccine in the Prevention of Influenza Illness During Early Infancy and in Mothers: Randomized Controlled Phase III Trial Evaluating Safety, Immunogenicity and Efficacy
Brief Summary: Randomised, double blind, placebo controlled trial to assess safety, immunogenicity and efficacy of Trivalent Influenza vaccine in HIV uninfected pregnant women


Options:
A: Arm Label: Trivalent influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
B: Arm Label: Trivalent Influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent Influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
C: Intervention Type: BIOLOGICAL; Name: pneumococcal polysaccharide and protein conjugate vaccines; Assigned to Arm(s): N/A
D: Arm Label: Text message vaccine reminders; Type: EXPERIMENTAL; Interventions: Other: Text Message, Other: automated call | Arm Label: automated phone call from clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: automated call | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text message vaccine reminders | Intervention Type: OTHER; Name: automated call; Assigned to Arm(s): Text message vaccine reminders, automated phone call from clinic

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trivalent Influenza Vaccine in HIV-infected Pregnant Women and Kinetics of Transplacental Anti-influenza Antibody Transfer and Persistence in Young Infants: A Randomized Controlled Phase II Trial Evaluating Safety and Immunogenicity
Brief Summary: This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of transplacental anti-influenza antibody transfer to their newborns and kinetics thereof during early infancy.


Options:
A: Arm Label: Influenza vaccine; Type: EXPERIMENTAL; Interventions: Biological: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Phosphate buffered saline | Intervention Type: BIOLOGICAL; Name: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived); Assigned to Arm(s): Influenza vaccine | Intervention Type: OTHER; Name: Phosphate buffered saline; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: Fluarix vaccine; Assigned to Arm(s): N/A
C: Arm Label: TIV + aH5N1; Type: EXPERIMENTAL; Interventions: Biological: Trivalent influenza virus vaccine (TIV), Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1) | Arm Label: PL + aTIV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo (PL), Biological: Adjuvanted trivalent influenza virus vaccine (aTIV) | Intervention Type: BIOLOGICAL; Name: Placebo (PL); Assigned to Arm(s): PL + aTIV | Intervention Type: BIOLOGICAL; Name: Trivalent influenza virus vaccine (TIV); Assigned to Arm(s): TIV + aH5N1 | Intervention Type: BIOLOGICAL; Name: Adjuvanted monovalent influenza virus vaccine (aH5N1); Assigned to Arm(s): TIV + aH5N1 | Intervention Type: BIOLOGICAL; Name: Adjuvanted trivalent influenza virus vaccine (aTIV); Assigned to Arm(s): PL + aTIV
D: Arm Label: Trivalent Influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent Influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trivalent Influenza Vaccine in HIV-infected Pregnant Women and Kinetics of Transplacental Anti-influenza Antibody Transfer and Persistence in Young Infants: A Randomized Controlled Phase II Trial Evaluating Safety and Immunogenicity
Brief Summary: This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of transplacental anti-influenza antibody transfer to their newborns and kinetics thereof during early infancy.


Options:
A: Intervention Type: BIOLOGICAL; Name: pneumococcal polysaccharide and protein conjugate vaccines; Assigned to Arm(s): N/A
B: Arm Label: Trivalent Influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent Influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
C: Arm Label: Text message vaccine reminders; Type: EXPERIMENTAL; Interventions: Other: Text Message, Other: automated call | Arm Label: automated phone call from clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: automated call | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text message vaccine reminders | Intervention Type: OTHER; Name: automated call; Assigned to Arm(s): Text message vaccine reminders, automated phone call from clinic
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Influenza Vaccine Intervention; Type: EXPERIMENTAL; Interventions: Other: Influenza Vaccine Intervention | Intervention Type: OTHER; Name: Influenza Vaccine Intervention; Assigned to Arm(s): Influenza Vaccine Intervention

Answer: B